BCL partner John Binns and senior associate David Hardstaff write for Cannabis Wealth discussing the regulatory landscape in the UK following the EFSA’s decision to pause all novel foods evaluations for CBD products.
UK-based CBD companies may feel they have had a rough ride recently as the FSA introduces the new novel food application process, which requires non-medicinal CBD products to be the subject of an application for authorisation. BCL partner John Binns and senior associate David Hardstaff explore the changes in the UK CBD industry in their recent article for Open Government Access.
BCL partner John Binns and associate David Hardstaff ask if a new report should put a spring in the step of UK businesses with an interest in medicinal cannabis and cannabidiol (CBD) in their article published by Open Access Government.
The Financial Conduct Authority (FCA) is consulting on a Technical Note about listings of cannabis-related businesses.John Binns explains why the Note, though welcome, leaves some vital questions still unanswered.
BCL partner John Binns and Associate David Hardstaff’s article ‘Can the UK Solve its ‘Money Laundering” Problem with the Proceeds of Medicinal Cannabis?’ has been published by International Pharmaceutical Industry Magazine.